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Purpose
The American College of Chest Physicians (ACCP) produced an evidence-based guideline on
treatment of patients with small-cell lung cancer (SCLC). Because of the relevance of this
guideline to American Society of Clinical Oncology (ASCO) membership, ASCO reviewed the
guideline, applying a set of procedures and policies used to critically examine guidelines
developed by other organizations.
Methods
The ACCP guideline on the treatment of SCLC was reviewed for developmental rigor by
methodologists. An ASCO Endorsement Panel updated the literature search, reviewed the
content, and considered additional recommendations.
Results
The ASCO Endorsement Panel determined that the recommendations from the ACCP guideline,
published in 2013, are clear, thorough, and based on current scientific evidence. ASCO endorses
the ACCP guideline on the treatment of SCLC, with the addition of qualifying statements.
Recommendations
Surgery is indicated for selected stage I SCLC. Limited-stage disease should be treated with
concurrent chemoradiotherapy in patients with good performance status. Thoracic radiotherapy should
be administered early in the course of treatment, preferably beginning with cycle one or two of
chemotherapy. Chemotherapy should consist of four cycles of a platinum agent and etoposide.
Extensive-stage disease should be treated primarily with chemotherapy consisting of a platinum agent
plus etoposide or irinotecan. Prophylactic cranial irradiation prolongs survival in patients with limitedstage disease who achieve a complete or partial response to initial therapy and may do so in similarly
responding patients with extensive-stage disease as well. Additional information is available at
http://www.asco.org/endorsements/sclc and http://www.asco.org/guidelineswiki.
J Clin Oncol 33:4106-4111. © 2015 by American Society of Clinical Oncology

INTRODUCTION

Small-cell lung cancer (SCLC) represents approximately 10% to 15% of all lung cancers.1,2 The incidence of SCLC in the United States has been steadily
decreasing in the last two decades, mainly because of
reduction in cigarette consumption, the primary
cause of this tumor type.3 SCLC is characterized by
rapid growth, early metastasis, and initial sensitivity
to chemotherapy and radiotherapy.1,2 Unfortunately, despite initial response, patients with extensive disease develop drug resistance and die as a
result of disease at a median of 10 to 12 months from
diagnosis.1,2 In contrast, patients with limited disease can be successfully treated with combined concomitant chemoradiotherapy, which produces a

15% to 20% cure rate.4 The most important advances in the treatment of this disease in the last two
decades have been based on improvements in application of radiotherapy.3 Chest irradiation and
prophylactic brain irradiation have both been demonstrated to increase survival.3 However, few advancements have been made in systemic treatment,
with the last drug approved by the US Food and
Drug Administration being topotecan in 1998.
The purpose of this American Society of Clinical Oncology (ASCO) guideline is to review and
endorse the American College of Chest Physicians
(ACCP) guideline on the treatment of SCLC by Jett
et al5 published in Chest in 2013. This ASCO endorsement reinforces the recommendations offered
in the ACCP guideline and acknowledges the effort
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THE BOTTOM LINE
ASCO Endorses the ACCP Clinical Practice Guideline on the Treatment of Small-Cell Lung Cancer, With Minor
Qualifying Statements
Guideline Questions

1. In patients with small-cell lung cancer (SCLC), what is the ability of positron emission tomography (PET) imaging to
determine the stage of cancer?
2. In patients with limited-stage (LS) SCLC, how do the parameters of thoracic radiotherapy (TRT) affect survival?
3. In patients with extensive-stage (ES) SCLC, what is the survival after treatment with chemotherapy, including novel and
targeted agents?
4. In elderly patients with SCLC, what are survival and toxicity after treatment with chemotherapy or radiation
therapy?
Target Population
Patients with SCLC
Target Audience
Primary care providers, oncologists, radiologists, pathologists, and other health providers
Methods
An American Society of Clinical Oncology (ASCO) Endorsement Panel was convened to consider endorsing the American College of
Chest Physicians (ACCP) guideline recommendations on the treatment of SCLC, which were based on a systematic review of the
medical literature. The ASCO Endorsement Panel considered the methodology employed in the ACCP guideline using the Appraisal of
Guidelines for Research and Evaluation II (AGREE II) review instrument. The ASCO Endorsement Panel carefully reviewed the ACCP
guideline content to determine appropriateness for ASCO endorsement.
ASCO Key Recommendations for Treatment of SCLC
ASCO qualifying statements appear in bold italics (with remarks shown in italics). Data Supplement 1 provides a reprint of all the
ACCP recommendations.
●

In patients with SCLC (proven or suspected), a staging evaluation is recommended consisting of a medical history and
physical examination, CBC and comprehensive chemistry panel with renal and hepatic function tests, CT [computed
tomography] of the chest and abdomen with intravenous contrast or CT scan of the chest extending through the liver and
adrenal glands, MRI [magnetic resonance imaging] or CT of the brain, and bone scan (grade 1B). If PET is obtained,
then bone scan may be omitted. CBC should include differential.

●

In patients with clinically LS SCLC, PET imaging is suggested (grade 2C). Remark: If PET is obtained, then bone scan may
be omitted. PET scan use is also applicable to ES SCLC.

●

In patients with SCLC, it is recommended that both the Veterans’ Administration system (LS v ES) and the American
Joint Committee on Cancer/International Union Against Cancer seventh edition system (TNM) should be used to classify
the tumor stage (grade 1B).

●

In patients with clinical stage I SCLC, who are being considered for curative intent surgical resection, invasive mediastinal
staging and extrathoracic imaging (head MRI/CT and PET or abdominal CT plus bone scan) are recommended (grade
1B).

●

In patients with clinical stage I SCLC, after a thorough evaluation for distant metastases and invasive mediastinal stage
evaluation, surgical resection is suggested over nonsurgical treatment (grade 2C).

●

In patients with stage I SCLC who have undergone curative-intent surgical resection, platinum-based adjuvant
chemotherapy is recommended (grade 1C).
(continued on following page)
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THE BOTTOM LINE (CONTINUED)
●

In patients with LS SCLC, early chemoradiotherapy, with accelerated hyperfractionated radiation therapy (twice-daily
treatment) concurrently with platinum-based chemotherapy, is recommended (grade 1B). Comparison of accelerated
hyperfractionated radiotherapy with an extended course of daily radiation therapy at standard fractionation is
currently being investigated.

●

In patients with LS or ES SCLC who achieve a complete or partial response to initial therapy, prophylactic cranial
irradiation [PCI] is recommended (grade 1B). Remark: The regimen of 25 Gy in 10 daily fractions has the greatest supporting
data for safety and efficacy. The panel notes that a recent Japanese study failed to demonstrate survival advantage
with PCI in patients with ES SCLC. On publication of the mature data from this study, the recommendation for
PCI in ES SCLC might be subject to revision.

●

In patients with ES SCLC who have completed chemotherapy and achieved a complete response outside the chest and
complete or partial response in the chest, a course of consolidative TRT is suggested (grade 2C). Further evaluation of
this question is required before a treatment recommendation can be made.

●

In patients with either LS or ES SCLC, four to six cycles of platinum-based chemotherapy with either cisplatin or
carboplatin plus either etoposide or irinotecan are recommended over other chemotherapy regimens (grade 1A). Clinical
trials in the United States and Europe have not demonstrated a benefit for the irinotecan regimen over that based
on etoposide. In LS disease, four cycles is preferred.

●

In patients with relapsed or refractory SCLC, the administration of second-line, single-agent chemotherapy is
recommended (grade 1B). Remark: Reinitiation of the previously administered first-line chemotherapy regimen is
recommended in patients who experience relapse 6 months from completion of initial chemotherapy. Enrollment onto a clinical
trial is encouraged. Single-agent topotecan has US Food and Drug Administration approval in this context.

●

In elderly patients with LS SCLC and good performance status (PS; Eastern Cooperative Oncology Group [ECOG] 0 to 2),
treatment with platinum-based chemotherapy plus TRT is suggested, with close attention to management of treatmentrelated toxicity (grade 2B).

●

In elderly patients with ES SCLC and good PS (ECOG 0 to 2), treatment with carboplatin-based chemotherapy is
suggested (grade 2A).

●

In elderly patients with SCLC and poor PS, treatment with chemotherapy is suggested if the poor PS is due to SCLC (grade 2C).

Additional Resources
More information, including a Data Supplement, a Methodology Supplement, slide sets, and clinical tools and resources, is available at
http://www.asco.org/endorsements/sclc and http://www.asco.org/guidelineswiki. Patient information is available at http://www
.cancer.net.
A link to the ACCP guideline recommendations on treatment of SCLC can be found at http://www.chestnet.org/.
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have
the opportunity to participate.

put forth by the ACCP to produce an evidence-based guideline informing practitioners who care for patients with SCLC. The issues
addressed in the original guideline as well as this endorsement concern
the diagnosis and management of patients with SCLC. A reprint of all
the ACCP recommendations is provided in Data Supplement 2 and
online at http://journal.publications.chestnet.org/article.aspx?article
ID⫽1685799#SummaryofRecommendations.

goal of guideline endorsement is to increase the number of highquality, ASCO-vetted guidelines available to the ASCO membership.
The ASCO endorsement process involves an assessment by ASCO
staff of candidate guidelines for methodologic quality using the Rigour
of Development subscale of the Appraisal of Guidelines for Research
and Evaluation II (AGREE II) instrument (details provided in Methodology Supplement).

OVERVIEW OF ASCO GUIDELINE ENDORSEMENT PROCESS

Disclaimer
The clinical practice guideline and other guidance published
herein are provided by ASCO to assist providers in making clinical
decisions. The information herein should not be relied on as being

ASCO has policies and procedures for endorsing practice guidelines
that have been developed by other professional organizations. The
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complete or accurate, nor should it be considered as inclusive of all
proper treatments or methods of care or as a statement of the standard
of care. With the rapid development of scientific knowledge, new
evidence may emerge between the time information is developed and
when it is published or read. The information is not continually
updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified herein and is not
applicable to other interventions, diseases, or stages of disease. This
information does not mandate any particular course of medical care.
Furthermore, the information is not intended to substitute for the
independent professional judgment of the treating provider, because
the information does not account for individual variation among
patients. Each recommendation reflects high, moderate, or low confidence that the recommendation reflects the net effect of a given
course of action. The use of words like “must,” “must not,” “should,”
and “should not” indicate that a course of action is recommended or
not recommended for either most or many patients, but there is
latitude for the treating physician to select other courses of action in
individual patient cases. In all cases, the selected course of action
should be considered by the treating provider in the context of treating
the individual patient. Use of the information is voluntary. ASCO
provides this information on an as-is basis and makes no warranty,
express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use
or purpose. ASCO assumes no responsibility for any injury or damage
to persons or property arising out of or related to any use of this
information or for any errors or omissions.
Guideline and Conflicts of Interest
The ASCO Expert Panel (members listed in Appendix Table A1,
online only) was assembled in accordance with the ASCO Conflicts of
Interest Management Procedures for Clinical Practice Guidelines
(summarized at http://www.asco.org/rwc). Members of the panel
completed the ASCO disclosure form, which requires disclosure of
financial and other interests that are relevant to the subject matter of
the guideline, including relationships with commercial entities that
are reasonably likely to experience direct regulatory or commercial
impact as a result of promulgation of the guideline. Categories for
disclosure include employment; leadership; stock or other ownership;
honoraria; consulting or advisory role; speaker’s bureau; research
funding; patents, royalties, and other intellectual property; expert testimony; travel, accommodations, and expenses; and other relationships. In accordance with these procedures, the majority of the
members of the panel did not disclose any such relationships.

CLINICAL QUESTIONS AND TARGET POPULATION

An electronic search strategy of the literature performed in constructing the ACCP guideline focused on four principal questions: (1) In
patients with SCLC, what is the ability of positron emission tomography (PET) imaging to determine the stage of cancer? (2) In patients
with limited stage (LS) SCLC, how do the parameters of thoracic
radiotherapy (TRT) affect survival? (3) In patients with extensivestage (ES) SCLC, what is the survival after treatment with chemotherapy, including novel and targeted agents? (4) In elderly patients with
SCLC, what is the survival and toxicity after treatment with chemowww.jco.org

therapy or radiotherapy? The target population for the ACCP guideline is patients with SCLC.

SUMMARY OF SCLC TREATMENT GUIDELINE
DEVELOPMENT METHODOLOGY

The ACCP guideline was developed by an author expert panel and a
scientific advisory panel that included experts in oncology, pathology,
and methodology. The literature search of MEDLINE, Embase, and
five Cochrane databases (Cochrane Database of Systematic Reviews,
Database of Abstracts of Reviews of Effects, Cochrane Central Register
of Controlled Trials, Health Technology Assessment, and National
Health Service Economic Evaluation Database) spanned 2004 through
2011. The search included all levels of evidence (randomized controlled
trials [RCTs] and observational studies) as long as they appeared in peerreviewed publications, the minimal threshold. Details of the search strategies and study inclusion criteria and outcomes of interest are available at
http://journal.publications.chestnet.org/data/Journals/CHEST/926876/
chest_143_5_suppl_e400S.pdf. The searches identified studies for inclusion in the guideline qualitative synthesis of the literature. The ACCP
panel reviewed RCTs as well as observational studies.

RESULTS OF ASCO METHODOLOGY REVIEW

The methodology review of the ACCP guideline was completed independently by two ASCO guideline staff members using the Rigour of
Development subscale from the AGREE II instrument. Detailed results of the scoring for this guideline are available on request to
guidelines@asco.org. Overall, the ACCP guideline on treatment of
SCLC scored 89% on the Rigour subscale. The methodology was not
described in detail in the actual guideline but rather in supplementary
material that covered other topics on diagnosis and management of
lung cancer. The preliminary ASCO content reviewers of the treatment of SCLC guideline as well as the ASCO Endorsement Panel
found the recommendations well supported in the original guideline.
Each section, including introduction, methods, results, and recommendations sections, was clear and well referenced from the systematic review.

METHODS AND RESULTS OF ASCO UPDATED
LITERATURE REVIEW
ASCO guidelines staff updated the ACCP guideline on treatment of SCLC
literature search. Using the Ovid platform, the following databases were
searched from 2011 to March 2015: Medline, Embase, Cochrane Database of
Systematic Reviews, Cochrane Database of Abstracts of Reviews of Effects,
Cochrane Central Register of Trials, Health Technology Assessments Database, and National Health Service Economic Evaluations Database. The search
was restricted to articles published in English and to systematic reviews, metaanalyses, and RCTs.
The updated search yielded 1,169 articles. A review of these results
revealed no definitive evidence that would warrant substantive modification of the treatment of SCLC practice recommendations. The committee
did wish to clarify or comment on some areas of recent controversy and
ongoing research.
© 2015 by American Society of Clinical Oncology
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RESULTS OF ASCO CONTENT REVIEW

The ASCO Endorsement Panel reviewed the ACCP guideline on
treatment of SCLC and concurs that the recommendations are
clear, thorough, and based on relevant scientific evidence in this
content area and present options that will be acceptable to patients
and clinicians. Overall, the ASCO Endorsement Panel agrees with
the recommendations as stated in the guideline. The grading system and remarks were left as it, but the panel included several
qualifying statements. Details of the ACCP grading system can be
found in Data Supplement 3.
DISCUSSION

The ASCO Endorsement Panel wants to highlight and qualify some of
the statements from the ACCP guideline on the treatment of SCLC.
Overall, the panel was in agreement with the 14 recommendation
statements included in the ACCP guideline. However, the panel believed it would be beneficial to include qualifying statements to six of
these recommendations. The areas of concern are discussed as follows:
PET Scanning in SCLC
There was overall consensus that in patients with SCLC, a staging
evaluation should be performed, which should include a medical
history and physical examination, CBC and comprehensive chemistry
panel with renal and hepatic function tests, computed tomography
(CT) scan of the chest and abdomen with intravenous contrast or CT
scan of the chest extending through the liver and adrenal glands,
magnetic resonance imaging or CT of the brain, and bone scan. However, the panel recognizes that PET scanning has become an increasingly widely used initial staging tool in patients with lung cancer. If a
PET scan is obtained, a bone scan may then be omitted. In addition,
when obtaining the CBC, the differential should be included. These
qualifying statements apply to patients with both LS and ES disease.
TRT Schedule in LS SCLC
The use of early chemoradiotherapy, with accelerated hyperfractionated radiation therapy (twice-daily treatment) concurrently with
platinum-based chemotherapy, in patients with LS SCLC is recommended.4 The panel wishes to remind the oncology community that
there are ongoing studies comparing accelerated hyperfractionated
radiotherapy with an extended course of daily radiation therapy
at standard once-daily fractionation (ClinicalTrials.gov identifier
NCT00632853). This recommendation may need to be revisited when
results from these studies are published.
Prophylactic Cranial Irradiation in ES Disease
Prophylactic cranial irradiation (PCI) is recommended in patients with LS or ES SCLC who achieve a complete or partial response
to initial therapy. The committee is aware of a recently completed
study by Seto et al,6 presented at the ASCO 2014 annual meeting,
REFERENCES
1. van Meerbeeck JP, Fennell DA, De Ruysscher
DK: Small-cell lung cancer. Lancet 378:1741-1755,
2011
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which reportedly failed to demonstrate a survival advantage for PCI in
163 patients with ES SCLC who, after response to first-line therapy,
were randomly assigned to either PCI (25 Gy in 10 fractions) or
observation without PCI. The panel notes that final results of this
study have not appeared in a peer-reviewed journal. On publication
and review of the mature data from this study, the recommendation
for PCI in ES SCLC might be subject to revision.
Consolidative TRT in ES SCLC
In patients with ES SCLC who have completed chemotherapy
and achieved a complete response outside the chest and complete or
partial response in the chest, a course of consolidative TRT is suggested. The panel raised some concerns with regard to the strength of
the available evidence on this topic. They agreed that further evaluation of this question is needed before an actionable recommendation
can be made and noted that additional studies are in progress.
Choice and Duration of First-Line Chemotherapy
Four to six cycles of platinum-based chemotherapy with either
cisplatin or carboplatin plus either etoposide or irinotecan are recommended over other chemotherapy regimens in patients with either LS
or ES SCLC. The panel noted that clinical trials in the United States
and Europe have not demonstrated a benefit for the irinotecan regimen over that containing etoposide.7-9 The panel also agreed that in
LS disease, four cycles of platinum-based chemotherapy are preferred.
ENDORSEMENT RECOMMENDATION

ASCO endorses the ACCP guideline on the treatment of SCLC published by Jett et al5 in 2013 in Chest, with minor qualifying statements.
ADDITIONAL RESOURCES

More information, including a Data Supplement with a reprint of all
treatment of SCLC recommendations (original guideline), a Methodology Supplement, slide sets, and clinical tools and resources, is available
at http://www.asco.org/endorsements/sclc and http://www.asco.org/
guidelineswiki. Patient information is available at http://www.cancer.net
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John Hopkins University, Baltimore, MD
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
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Lung Cancer Foundation of America, Marina del Rey, CA
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Medical oncologist
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Medical oncologist
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